Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM22 versus pegfilgrastim in breast cancer patients receiving chemotherapy
ISRCTN18217390Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial in breast cancer comparing XM22 with Pegfilgrastim (2 arms). Primary endpoint: Duration of severe neutropenia in cycle 1. Started May 2010; status: completed.
02
Drugs
lipegfilgrastimpegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN18217390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18217390.